CN105998150A

CN105998150A - Neurodermatitis treating medicine

Info

Publication number: CN105998150A
Application number: CN201610582736.3A
Authority: CN
Inventors: 万强胜
Original assignee: Individual
Current assignee: Individual
Priority date: 2016-07-23
Filing date: 2016-07-23
Publication date: 2016-10-12

Abstract

The invention relates to a preparation for external use, in particular to a neurodermatitis treating medicine which is effective in neurodermatitis treatment, low in cost, free of side effects and high in cure rate. In order to solve technical problems, the technical scheme includes that the neurodermatitis treating medicine is prepared from, by volume percent, 0.8-1.3% of menthol, 0.8-1.3% of salicylic acid, 0.8-1.3% of resorcin, 3.6-6.3% of coal tar, 4-6% of castor oil and the balance 95% ethyl alcohol.

Description

A kind of medicine treating neurodermatitis

Technical field

The present invention relates to a kind of external preparation, be specifically related to a kind of medicine treating neurodermatitis.

Background technology

Neurodermatitis is a kind of dysfunction dermatoses.Factor of curing the disease is it is now recognized that Nervous and Mental Factors is the main inducing that primary disease occurs, and anxious state of mind, spirit hypertonicity, anxious, living environment change suddenly etc. all can aggravate disease and repeatedly.Additionally infect such as gastrointestinal dysfunction, hormonal system dysfunction, internal chronic lesion, local excitation etc., be all likely to become paathogenic factor.

Neurodermatitis has obvious skin lesion, and violent pruritus is its cardinal symptom.Be mainly in cervical region, extremity stretch side, lumbosacral region, nest, pudendum etc..Often recurrent exerbation, clinic are difficult to cure.

Summary of the invention

For overcoming the deficiencies in the prior art, the invention provides a kind of medicine treating neurodermatitis, can effectively treat neurodermatitis, with low cost, have no side effect and cure rate is high.

For solving above-mentioned technical problem, the technical solution adopted in the present invention is: a kind of medicine treating neurodermatitis, is made up of the raw material of volumes below percentage ratio:

Mentholum 0.8-1.3%, salicylic acid 0.8-1.3%, resorcin 0.8-1.3%, coal tar 3.6-6.3%, Oleum Ricini 4-6%, surplus is 95% ethanol.

A kind of medicine treating neurodermatitis, is made up of the raw material of volumes below percentage ratio:

Mentholum 1%, salicylic acid 1%, resorcin 1%, coal tar 5%, Oleum Ricini 5%, surplus is 95% ethanol.

The pharmacological action of above-mentioned raw materials is as follows:

Mentholum, refrigerant antipruritic, stimulate human body cold sensation reflection sensor, cause skin mucosa to shrink；

Salicylic acid, has the strongest exfoliation, the effect of cleaning skin pore, and safety is high, suppresses antibacterial, kills antifungal effect good；

Resorcin, can kill antibacterial and fungus, has antipruritic, to dissolve cutin effect；

Coal tar, contributes to the fast breeding of delaying skin cell, so that skin recovers normal performance, reduces inflammation, pruritus and squama；

Oleum Ricini, detumescence and drawing out poison, dredging collateral profit key, main swollen ulcer drug, scabies abdominal mass tinea skin ulcer, can be as skin lubrication agent

95% ethanol, is respectively provided with killing action, but blood spreads, increase local blood circulation antibacterial and most of microbe.

The processing technology of the present invention: aseptically, measures raw material in described ratio, first adds in 95% ethanol by coal tar and Oleum Ricini, after fully dissolving, sequentially adds Mentholum, salicylic acid and resorcin, sealed storage after being thoroughly mixed uniformly.

Compared with prior art the method have the advantages that neurodermatitis can effectively be treated by the medicine of the present invention, with low cost, have no side effect and cure rate is high.

Detailed description of the invention

Below in conjunction with specific embodiment, the invention will be further described.

Embodiment 1

Mentholum 1%, salicylic acid 1%, resorcin 1%, coal tar 5%, Oleum Ricini 5%, surplus is 95% ethanol；

Aseptically, measuring raw material in described ratio, first add in 95% ethanol by coal tar and Oleum Ricini, after fully dissolving, sequentially add Mentholum, salicylic acid and resorcin, after being thoroughly mixed uniformly, sealed storage is standby.

Embodiment 2

Mentholum 1.3%, salicylic acid 0.8%, resorcin 1.3%, coal tar 5.5%, Oleum Ricini 4.5%, surplus is 95% ethanol；

Embodiment 3

Mentholum 1.2%, salicylic acid 1.3%, resorcin 1%, coal tar 6.3%, Oleum Ricini 4%, surplus is 95% ethanol；

Embodiment 4

Mentholum 0.9%, salicylic acid 1.1%, resorcin 0.8%, coal tar 3.6%, Oleum Ricini 6%, surplus is 95% ethanol；

Embodiment 5

Mentholum 0.8%, salicylic acid 0.8%, resorcin 1%, coal tar 4.8%, Oleum Ricini 5.5%, surplus is 95% ethanol；

Comparative example

(1) sending out skin lesion to new, lichenization relatively gently has again the blood crusts vestige scratched, and be distributed in neck both sides, dermatitis near the eyes, or fossa cubitalis position should select momestasone furoate frost or Econazole Compound white, every day 2 times；

(2) be distributed in elbow, sacrum, knee hypertrophica lichenification skin lesion select skin disease peaceful plaster external application, the next day change once；

(3) to generalized neurodermatitis, the skin lesion of whole body, extremity external 0.04% ground ketone lotion, 005% fluocinolone acetonide dimethyl sulfoxide liniment almost it are covered with；Put on the skin outside trunk skin lesion and put on the skin outside phenol Calamine Lotion, or the antipruritic solution of antiallergic.

The present inventor selects 100 patients that medicine is carried out clinical observation.After distinguishing by above-mentioned three types, random assortment, comparative example treatment group is followed successively by 25 examples, 13 examples, 10 examples；Treatment group of the present invention is followed successively by 27 examples, 13 examples, 12 examples；The usage of the present invention is every day 2 times, and serious symptom is three times a day.

Treatment standard: before and after treatment, does not improve, for invalid；Before and after treatment, remission is for taking a turn for the better；Before and after treatment, without recurrence in transference cure and March.Experimental result is shown in Table 1

Table 1 embodiment and the therapeutic effect of comparative example

As can be seen from Table 1, the therapeutic effect of the present invention is compared traditional therapy and is had clear superiority.

The present invention can summarize with other the concrete form without prejudice to the spirit or essential characteristics of the present invention.Therefore, no matter from the point of view of which point, the embodiment above of the present invention all can only be considered the description of the invention and can not limit invention, claims indicate the scope of the present invention, and the scope of the present invention is not pointed out in above-mentioned explanation, therefore, any change in the implication suitable with claims of the present invention and scope, all it is considered as being included within the scope of the claims.

Claims

1. the medicine treating neurodermatitis, it is characterised in that be made up of the raw material of volumes below percentage ratio:

A kind of medicine treating neurodermatitis the most according to claim 1, it is characterised in that: it is made up of the raw material of volumes below percentage ratio:

A kind of medicine treating neurodermatitis the most according to claim 1 and 2, it is characterized in that being prepared as follows: aseptically, raw material is measured in described ratio, first coal tar and Oleum Ricini are added in 95% ethanol, after fully dissolving, sequentially add Mentholum, salicylic acid and resorcin, sealed storage after being thoroughly mixed uniformly.